I Tried Retatrutide – Here's What Happened
In a Nutshell
Retatrutide is a triple-agonist (GLP-1/GIP/glucagon) that drives ~25% weight loss by both cutting appetite and raising energy expenditure, with the glucagon pathway increasing resting heart rate over 50% and core temperature ~1.2 °F. In the speaker’s one-month self-experiment at 1–2 mg/week, 4,000+ kcal intake still produced 12 lb loss and a drop from ~5% to 3.2% body fat, while strength remained stable and LDL/ApoB unexpectedly fell—likely via glucagon-mediated PCSK9 inhibition. The two paradoxes (increased hunger, muscle sparing) arise because lean users are more FGF21-sensitive, so metabolic-rate elevation can outpace appetite suppression and may protect muscle; however, clinical data still show ~38% lean-mass loss, and hs-CRP rose secondary to sleep disruption.
These notes were generated by AI and may contain inaccuracies.
Retatrutide is described as potentially the biggest weight loss drug in history. In published trials, people taking retatrutide lost a quarter of their body weight in under a year. The drug is 60% stronger than Ozempic and outperforms all other weight loss drugs significantly.
The speaker tried retatrutide despite being lean, motivated by curiosity about unusual reports: people getting hungrier on the drug, claims of shedding body fat without losing muscle, and even building muscle. The experiment was conducted to investigate these claims, not for health reasons, and carried potential health risks. 127 biomarkers were tracked before and after to observe metabolic changes.
The speaker notes eating over 4,000 calories per day and still losing 4 lb in the first week. Resting heart rate increased over 50%, and the speaker ended up sick on the bathroom floor. The core questions addressed are whether these drugs should be used and whether users should stay on them long-term.
The video roadmap includes five parts: why retatrutide differs from other weight loss drugs, unpacking two paradoxes about retatrutide, the speaker's personal experience including unexpected effects and blood markers, resolving the retatrutide paradoxes, and answering whether one should use these drugs.
Retatrutide, sometimes called reta or informally GLP-3, is the next evolution in GLP-1 receptor agonist weight loss drugs. First-generation drugs like Ozempic and Wegovy target only the GLP-1 receptor, which reduces hunger. Second-generation drugs like tirzepatide (Mounjaro, Zepbound) target GLP-1 plus the GIP pathway, which improves how the body partitions fuel and supports fat cells releasing fatty acids during fasting.
Sign in to read the full notes
Get access to AI-generated notes, topic timestamps, and more.